Literature DB >> 28816982

Performance of procalcitonin in diagnosing parapneumonic pleural effusions: A clinical study and meta-analysis.

Chao He1, Bo Wang, Danni Li, Huan Xu, Yongchun Shen.   

Abstract

BACKGROUND: Parapneumonic pleural effusion (PPE) is a common complication of pneumonia. The accurate diagnosis of PPE remains a challenge. Recent studies suggest that procalcitonin (PCT) emerges as a potential biomarker for PPE. Our study aimed to determine the diagnostic value of PCT for PPE by a clinical study and summarize the overall diagnostic performance of PCT through a meta-analysis.
METHODS: Demographic and clinical data of the patients with PPE and controls were collected in our clinical study. The diagnostic performances of serum PCT (s-PCT) were analyzed via receiver operating characteristic (ROC) curve analysis, using area under the curve (AUC) as a measure of accuracy. Literature databases were systematically searched for the studies examining the accuracy of PCT for diagnosing PPE. Data on sensitivity, specificity, positive/negative likelihood ratio (PLR/NLR), and diagnostic odds ratio (DOR) were pooled. Summary ROC curves and AUC were used to evaluate overall test performance.
RESULTS: In our clinical study, 47 patients with PPE and 101 controls were included. The s-PCT levels were significantly increased in the setting of PPE (5.44 ± 9.82 ng/mL) compared with malignant PE (0.15 ± 0.19 ng/mL), tuberculous PE (0.18 ± 0.16 ng/mL), and transudates (0.09 ± 0.03 ng/mL) (P < .001). Using a cutoff value of 0.195 ng/mL, the sensitivity and specificity of s-PCT in diagnosing PPE were 0.83 and 0.80, respectively, and AUC was 0.89. In addition, 11 studies were included in our meta-analysis. Summary performance estimates for s-PCT in diagnosing PPE were as follows: sensitivity, 0.78 (95% CI: 0.71-0.84); specificity, 0.74 (95% CI: 0.69-0.78); PLR, 3.46 (95% CI: 2.09-5.74); NLR, 0.27 (95% CI: 0.14-0.54); DOR, 12.37 (95% CI: 4.34-41.17); and AUC, 0.84. The corresponding estimates for p-PCT were as follows: sensitivity, 0.62 (95% CI: 0.57-0.67); specificity, 0.71 (95% CI: 0.68-0.75); PLR 2.31 (95% CI: 1.81-2.95); NLR, 0.47 (95% CI: 0.35-0.63); DOR, 5.48 (95% CI: 3.07-9.77); and AUC, 0.80.
CONCLUSION: Both s-PCT and p-PCT might have modest performance in diagnosing PPE. However, more studies on a large scale should be performed to confirm our findings.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28816982      PMCID: PMC5571719          DOI: 10.1097/MD.0000000000007829

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


Introduction

Pneumonia is reported as the most common cause of infection-related mortality worldwide.[ Parapneumonic pleural effusion (PPE) refers to a pleural effusion (PE) associated with bacterial pneumonia, a pulmonary abscess, or infected bronchiectasis.[ PPE occurs in 45% of the patients who are hospitalized with pneumonia, and up to 35% of these patients develop an empyema which results in a prolonged hospital stay and higher mortality.[ It highlights the early diagnosis of PPE as paramount in the evaluation of patients with pneumonia. The diagnosis of PPE is a challenge because of the limitations of the current available methods. PE culture is negative in 40% of cases of PPE.[ Detection of pH, lactate dehydrogenase (LDH), and glucose in PE shows a low specificity and/or low sensitivity.[ In addition, radiologic examination and cytological analyses can be used to distinguish PPE from other kinds of PE (such as malignant PE [MPE], tuberculous PE [TPE]). However, these methods are sometimes insufficient for exact diagnosis, especially in the early phase of the diseases. Therefore, biomarkers of bacterial metabolism and those of white cells, such as procalcitonin (PCT), C-reactive protein, and interleukin, have been looked at in the last few years to improve the diagnosis. PCT is a prohormone of calcitonin that is secreted physiologically by C-cells of the thyroid gland in response to hypercalcemia, and is emerging as a promising clinical biomarker of bacterial infection.[ PCT concentrations tend to be higher in patients with pneumonia who have more severe infections.[ In recent years, some studies have evaluated the usefulness of serum PCT (s-PCT) and/or pleural PCT (p-PCT) as a diagnostic marker of PPE. However, the conflicting conclusions were obtained.[ To gain more reliable insights, we analyzed the diagnostic accuracy of s-PCT level in PPE by a retrospective clinical study and summarized the overall performance of s-PCT and p-PCT for diagnosing PPE via an updated meta-analysis.

Methods

Patients

A total of 148 inpatients with PE admitted to West China Hospital during January 2015 to June 2016 were included in this study. A PPE was defined as one associated with pneumonia according to the criteria of the American Thoracic Society.[ A MPE was defined as one with malignant cells identified in the PE cytology or biopsy specimen. A TPE was regarded as one associated with granulomatous inflammation seen on the pleural biopsy specimen or a positive Mycobacterium tuberculosis culture finding in PE. A transudate was attributed to heart failure, liver cirrhosis, and chronic renal failure.[ Institutional review board approval was waived for this retrospective clinical study and meta-analysis.

Data collection and statistical analysis

Demographic data, concentration of s-PCT, and protein/LDH/glucose in PE were collected for the patients included, and summarized using descriptive statistics. The s-PCT level was measured by electrochemiluminescence method (Roche, IN). The data of s-PCT were expressed as the mean ± standard deviations. The differences between groups were analyzed using the one-way analysis of variance. A receiver operating characteristic (ROC) curve analysis was applied to evaluate the threshold value of s-PCT in diagnosing PPE. A cutoff point was determined as the value of the parameter that maximized the sum of the specificity and sensitivity. The area under the curve (AUC) was used to summarize the diagnostic performance of s-PCT. The statistical analysis was performed using SPSS 18.0 software (Chicago, IL). A value of P less than .05 was considered statistically significant.

Meta-analysis

A systematic literature search was conducted in PubMed, EMBASE, CNKI, WANGFANG, and VIP databases up to September 2016, using the following syntax: “Parapneumonic pleural effusion OR Parapneumonic pleural fluid OR Parapneumonic effusion OR Parapneumonic fluid” AND “Procalcitonin” AND “Sensitivity OR Specificity OR Accuracy.” Studies were included if they fulfilled the following criteria: they were original research articles and published in English or Chinese; they examined the ability of PCT level for diagnosing PPE in humans; and they reported sufficient data to allow calculation of true positive (TP), false positive (FP), false negative (FN), and true negative (TN). Conference proceedings and studies published only as abstracts were excluded. The quality of the selected studies was assessed using the 14-items Quality Assessment of Diagnostic Accuracy Studies (QUADAS) list.[ We calculated positive likelihood ratios (PLR), negative likelihood ratios (NLR), and diagnostic odds ratios (DOR), which used as an overall index of diagnostic accuracy. Summary receiver operating characteristic (SROC) curves and AUC were also calculated to evaluate the overall diagnostic performance of PCT. Heterogeneity was assessed using the I2 inconsistency test. I2 > 50% indicated substantial heterogeneity. Potential publication bias was evaluated by Deek funnel plot.[ All analyses were performed using the “Midas” module in STATA 12.0 (Stata Corp, College Station, TX) and Meta-DiSc 1.4 for Windows (XI, Cochrane Colloquium, Barcelona, Spain). All statistical tests were 2-sided, a P value less than .05 was considered as statistical significance.

Results

Demographics of the patients and their pleural effusion characteristics

The present clinical study included 47 patients in PPE group and 101 patients in control groups (including 46 patients with TPE, 41 with MPE, and 14 with transudate). The demographics and characteristics of PE in these patients are summarized in Table 1.
Table 1

Characteristics of the patients with pleural effusions in the present clinical study.

Characteristics of the patients with pleural effusions in the present clinical study.

s-PCT levels in the patients

The s-PCT levels were significantly higher in the patients with PPE (5.44 ± 9.82 ng/mL) than those in the patients with MPE (0.15 ± 0.19 ng/mL), TPE (0.18 ± 0.16 ng/mL), and transudate (0.09 ± 0.03 ng/mL) (P < .001) (Fig. 1).
Figure 1

Comparisons of s-PCT levels in patients between PPE and non-PPE groups. The levels of PCT for PPE, MPE, TPE, transudate groups were 5.44 ± 9.82, 0.15 ± 0.19, 0.18 ± 0.16, and 0.09 ± 0.03 ng/mL, respectively. MPE = malignant pleural effusion, PCT = procalcitonin, PPE = parapneumonic pleural effusion, s-PCT = serum procalcitonin, TPE = tuberculous pleural effusion.

Comparisons of s-PCT levels in patients between PPE and non-PPE groups. The levels of PCT for PPE, MPE, TPE, transudate groups were 5.44 ± 9.82, 0.15 ± 0.19, 0.18 ± 0.16, and 0.09 ± 0.03 ng/mL, respectively. MPE = malignant pleural effusion, PCT = procalcitonin, PPE = parapneumonic pleural effusion, s-PCT = serum procalcitonin, TPE = tuberculous pleural effusion.

Diagnostic performance of s-PCT in PPE

A ROC curve was created to summarize the diagnostic performance of s-PCT for PPE, and the AUC was 0.886 (Fig. 2). At a cutoff value of 0.195 ng/mL, and the sensitivity and specificity of s-PCT in diagnosing PPE were 0.83 and 0.80, respectively.
Figure 2

ROC curve for the diagnosis of PPE. The AUC for s-PCT is 0.89. AUC = area under the curve, PPE = parapneumonic pleural effusion, ROC = receiver operating characteristic, s-PCT = serum procalcitonin.

ROC curve for the diagnosis of PPE. The AUC for s-PCT is 0.89. AUC = area under the curve, PPE = parapneumonic pleural effusion, ROC = receiver operating characteristic, s-PCT = serum procalcitonin. In this meta-analysis, 11 studies involving 1320 subjects, comprising 463 patients with PPE and 857 controls, were included for a meta-analysis.[ The clinical characteristics of the patients as well as the QUADAS scores for the studies included are listed in Table 2. Diagnostic performance of s-PCT and p-PCT is described in Table 3. Figure 3 shows the SROC curve, with an AUC of 0.84 for s-PCT and 0.80 for p-PCT.
Table 2

Clinical summary of included studies examining the diagnostic performance of serum and pleural PCT in PPEs.

Table 3

Summary characteristics of diagnostic performance of serum and pleural PCT levels.

Figure 3

SROC curves for s-PCT and p-PCT as a diagnostic biomarker for PPE. The overall AUCs for s-PCT (A) and p-PCT (B) are 0.84 and 0.80, respectively. AUC = area under the curve, p-PCT = pleural procalcitonin, PPE = parapneumonic pleural effusion, s-PCT = serum procalcitonin, SROC = summary receiver operating characteristic.

Clinical summary of included studies examining the diagnostic performance of serum and pleural PCT in PPEs. Summary characteristics of diagnostic performance of serum and pleural PCT levels. SROC curves for s-PCT and p-PCT as a diagnostic biomarker for PPE. The overall AUCs for s-PCT (A) and p-PCT (B) are 0.84 and 0.80, respectively. AUC = area under the curve, p-PCT = pleural procalcitonin, PPE = parapneumonic pleural effusion, s-PCT = serum procalcitonin, SROC = summary receiver operating characteristic. The heterogeneity examination showed that the sensitivity and specificity presented with I2 values of 70.1% and 72.6% for s-PCT, and 75.1% and 38.9% for p-PCT, respectively. These results suggested that heterogeneity existed among the studies. However, we did not perform a meta-regression analysis to investigate the source of heterogeneity due to limited included studies. Publication bias was tested by the Deek funnel plot. As shown in Figure 4, the slope coefficient was associated with a P value of 0.60 for s-PCT and 0.18 for p-PCT, suggesting no evidence of publication bias.
Figure 4

Deek funnel plot to assess the likelihood of publication bias. (A) s-PCT and (B) p-PCT. p-PCT = pleural procalcitonin, s-PCT = serum procalcitonin.

Deek funnel plot to assess the likelihood of publication bias. (A) s-PCT and (B) p-PCT. p-PCT = pleural procalcitonin, s-PCT = serum procalcitonin.

Discussion

The differential diagnosis of PPE is of great importance in the clinical management of the patient with pneumonia. Many methods can be used for the diagnosis of PPE, but the absence of early, reliable, and minimally invasive biomarkers for PPE screening has been a limiting factor in clinical practice.[ In this study, we performed a clinical study to confirm the diagnostic performance of s-PCT. We found that the AUC, sensitivity, and specificity of s-PCT for diagnosing PPE were 0.89, 0.83, and 0.80, respectively. It indicated that s-PCT was a modest diagnostic marker for PPE, and further evaluation of its clinical practice is necessary. Recent reports found that s-PCT can predict the prognosis and response to antibiotic management for the patients with community acquired pneumonia.[ Moreover, there are 3 kinds of PPE (uncomplicated PPE, complicated PPE, and empyema). So, further studies could focus on the role of s-PCT in assessing the severity of PPE and outcome of the patients, which will better guide its clinical management. We also completed a meta-analysis using currently available publications and our study to update the overall diagnostic performance of PCT for PPE. Our results indicate that s-PCT is associated with higher overall sensitivity (0.78) and specificity (0.74) compared to p-PCT with overall sensitivity (0.62) and specificity (0.71). The SROC curves illustrate overall test performance, and depict the tradeoff between sensitivity and specificity. The SROC analysis demonstrates an AUC of 0.84 for s-PCT and 0.80 for p-PCT, which is suggestive of a better overall performance of s-PCT. DOR combines the sensitivity and specificity data into a single number ranging from 0 to infinity, with higher values indicating better discriminatory test performance.[ The mean pooled DOR in our meta-analysis was 12.37 for s-PCT and 5.48 for p-PCT, suggesting that s-PCT may be more helpful in diagnosing PPE. We subsequently examined the diagnostic accuracy of PCT by calculating PLR and NLR. The pooled PLR was 3.46 for s-PCT and 2.31 for p-PCT, which suggest that PPE patients have an approximately 3-fold chance of presenting a positive s-PCT result and 2-fold chance of presenting a positive p-PCT result than patients without PPE do. The pooled NLR was 0.27 for s-PCT and 0.47 for p-PCT, indicating that a negative PCT measurement result presents 27% likelihood for s-PCT and 47% likelihood for p-PCT of being an FN. In our meta-analysis, latest papers published in recent years were included. We suggest that s-PCT have better diagnostic performance than that of p-PCT, which is different from the results of a previous meta-analysis.[ In addition, we found that the cutoff values of PCT ranged from 0.075 to 0.275 ng/mL among included studies. Such variation of cutoff value might result from the differences in clinical characteristics of the subjects. Further work should aim to identify the cutoff values that can provide optimal diagnostic accuracy, especially for differentiating the different kinds of PPE. Several limitations of this study should be addressed. First, for the strict inclusion criteria, our meta-analysis analyzed only a limited number of studies. Another limitation was that our clinical study was retrospective and the p-PCT level and severity of PPE cannot be taken into considerations for the lack of the available data. Finally, we observed the heterogeneity among the studies in our meta-analysis. However, due to the limited number of studies included, we did not evaluate covariates as possible sources of the heterogeneity.[

Conclusion

Taken together, the findings of our study suggest that both s-PCT and p-PCT might have modest performance in diagnosing PPE. PCT-based clinical study on a large scale may elucidate whether it can be a useful and noninvasive diagnostic tool to complement current diagnosing procedures of PPE.
  29 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  The diagnostic odds ratio: a single indicator of test performance.

Authors:  Afina S Glas; Jeroen G Lijmer; Martin H Prins; Gouke J Bonsel; Patrick M M Bossuyt
Journal:  J Clin Epidemiol       Date:  2003-11       Impact factor: 6.437

3.  Predictors of prolonged stay in patients with community-acquired pneumonia and complicated parapneumonic effusion.

Authors:  Junghyun Kim; Jong Sun Park; Young-Jae Cho; Ho Il Yoon; Jae Ho Lee; Choon-Taek Lee; Hyo-Jeong Lim; Deog Kyeom Kim
Journal:  Respirology       Date:  2015-10-29       Impact factor: 6.424

4.  Usefulness of the British Thoracic Society and the American College of Chest Physicians guidelines in predicting pleural drainage of non-purulent parapneumonic effusions.

Authors:  José Manuel Porcel; Manuel Vives; Aureli Esquerda; Agustín Ruiz
Journal:  Respir Med       Date:  2005-10-25       Impact factor: 3.415

5.  Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia.

Authors:  Paula Ramírez; Miquel Ferrer; Verónica Martí; Soledad Reyes; Raquel Martínez; Rosario Menéndez; Santiago Ewig; Antoni Torres
Journal:  Crit Care Med       Date:  2011-10       Impact factor: 7.598

6.  Biomarkers of infection for the differential diagnosis of pleural effusions.

Authors:  J M Porcel; M Vives; G Cao; S Bielsa; A Ruiz-González; A Martínez-Iribarren; A Esquerda
Journal:  Eur Respir J       Date:  2009-06-18       Impact factor: 16.671

7.  Pleural fluid pentraxin-3 for the differential diagnosis of pleural effusions.

Authors:  Chang Dong Yeo; Jin Woo Kim; Mi Ran Cho; Ji Young Kang; Seung Joon Kim; Young Kyoon Kim; Sang Haak Lee; Chan Kwon Park; Sang Ho Kim; Mi Sun Park; Hyeon Woo Yim; Jong Y Park
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-12-24

Review 8.  Pleural effusion: diagnosis, treatment, and management.

Authors:  Vinaya S Karkhanis; Jyotsna M Joshi
Journal:  Open Access Emerg Med       Date:  2012-06-22

9.  Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies.

Authors:  Penny F Whiting; Marie E Weswood; Anne W S Rutjes; Johannes B Reitsma; Patrick N M Bossuyt; Jos Kleijnen
Journal:  BMC Med Res Methodol       Date:  2006-03-06       Impact factor: 4.615

10.  The potential of molecular diagnostics and serum procalcitonin levels to change the antibiotic management of community-acquired pneumonia.

Authors:  David Gilbert; Gita Gelfer; Lian Wang; Jillian Myers; Kristina Bajema; Michael Johnston; James Leggett
Journal:  Diagn Microbiol Infect Dis       Date:  2016-06-15       Impact factor: 2.803

View more
  8 in total

1.  Understanding diagnostic tests. Part 1.

Authors:  Juliana Carvalho Ferreira; Cecilia Maria Patino
Journal:  J Bras Pneumol       Date:  2017 Sep-Oct       Impact factor: 2.800

2.  Clinical study of serum procalcitonin level in patients with myocardial infarction complicated by pulmonary infection.

Authors:  Shiming Sun; Fengli Wang; Miao Yu; Jing Kang
Journal:  Exp Ther Med       Date:  2018-10-09       Impact factor: 2.447

3.  Diagnosis of Parapneumonia Pleural Effusion with Serum and Pleural Fluid Cell-Free DNA.

Authors:  Chih-Min Su; Chia-Te Kung; Sheng-Yuan Hsiao; Nai-Wen Tsai; Yun-Ru Lai; Chih-Cheng Huang; Hung-Chen Wang; Wei-Che Lin; Ben-Chung Cheng; Yu-Jih Su; Cheng-Hsien Lu
Journal:  Biomed Res Int       Date:  2019-03-04       Impact factor: 3.411

Review 4.  Procalcitonin: A promising tool or just another overhyped test?

Authors:  Robin Paudel; Prerna Dogra; Ashley A Montgomery-Yates; Angel Coz Yataco
Journal:  Int J Med Sci       Date:  2020-01-18       Impact factor: 3.738

Review 5.  Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy.

Authors:  Andrew W Creamer; Alice E Kent; Maha Albur
Journal:  Breathe (Sheff)       Date:  2019-12

6.  Nicotinamide phosphoribosyltransferase as a biomarker for the diagnosis of infectious pleural effusions.

Authors:  Jing Huang; Lun Guo; Hong-Wei Kang; Dan Lv; Wei Lin; Chao-Fen Li; Xue-Qin Huang; Qun-Li Ding
Journal:  Sci Rep       Date:  2021-10-26       Impact factor: 4.379

7.  Understanding diagnostic tests. Part 2.

Authors:  Cecilia Maria Patino; Juliana Carvalho Ferreira
Journal:  J Bras Pneumol       Date:  2017 Nov-Dec       Impact factor: 2.624

8.  A Study Investigating Markers in PLeural Effusion (SIMPLE): a prospective and double-blind diagnostic study.

Authors:  Yan-Qiu Han; Li Yan; Peng Li; Lei Zhang; Pei-Heng Ouyang; Zhi-De Hu
Journal:  BMJ Open       Date:  2019-08-01       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.